TPDB

3D PDB MODEL

Drag to rotate. Click a residue or atom to inspect it; the selected residue is highlighted in amber.

TPDB ID TPDB91556

Peptide_Name

BP100

Activity

Antibacterial Anticancer Antifungal Cell-penetrating Peptides Hemolysis Toxicity

Activity_category_statistics

Anti-infective peptides Cancer-related peptides Toxicity and safety peptides Delivery and barrier-penetrating peptides

Database_Source

AntiBP3 dbAMP DRAMP Peptipedia CancerPPD 2.0 dbACP AFP-GFuse Antifp Antifungipept CAFPdb CellPPD-MOD CPPsite3.0 PerseuCPP APD_complete HemoPI Hemolytic2 PD_Hemolysis

Sequence_Type

standard

Has_Modification No

Description A 11-aa standard natural multi-activity (Antibacterial, Anticancer, Antifungal, and other sources) peptide sequence curated from AntiBP3, dbAMP, DRAMP, and other sources, with an available 3D structural model.

Modification

C-terminal: Amidation

Sequence

KKLFKKILKYL-NH2

FASTA

>TPDB91556|Antibacterial;Anticancer;Antifungal;Cell-penetrating Peptides;Hemolysis;Toxicity|length=11
KKLFKKILKYL-NH2

Formula C72H124N16O13

Absent Amino Acids ARNDCEQGHMPSTWV

Common Amino Acids K

Mass 1421.88

PI 10.77

Basic Residues 5

Acidic Residues 0

Hydrophobic Residues 6

Net Charge +5

Boman Index 0.89

Hydrophobicity -0.191

Aliphatic Index 141.82

Half Life

Mammalian: 1.3 hour Yeast: 3 min E.coli: 2 min

Extinction Coefficient Cystines 1490

Absorbance 280nm 104.79

Polar Residues 1

number

0

A

0

R

0

N

0

D

0

C

0

E

0

Q

0

G

0

H

1

I

3

L

5

K

0

M

1

F

0

P

0

S

0

T

0

W

1

Y

0

V

Amino Acid Distribution

A: 0 R: 0 N: 0 D: 0 C: 0 E: 0 Q: 0 G: 0 H: 0 I: 1 L: 3 K: 5 M: 0 F: 1 P: 0 S: 0 T: 0 W: 0 Y: 1 V: 0

Length

11

Formula

C72H124N16O13

Mass

1421.88

PI

10.77

Net Charge

+5

Boman Index

0.89

Hydrophobicity

-0.191

C_terminal_Modification

Amidation

Chirality

L

Linear_or_Cyclic

Linear

N_terminal_Modification

Free

Nature

Antimicrobial

Origin

Icthyopthirius multifilis (Strain G5)

Evidence 1 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 30.4 ± 2.7 µM

Detail Source Activity Anticancer

Activity Measurement 30.4

Target

Cancer Type Leukemia Cancer

Cell Line K-562

Tissue Affected Blood

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2017

Other

Source Activity Label	Source Definition
Anticancer	CancerPPD 2.0 manually curated experimentally verified anticancer peptide/protein annotation.

Evidence 2 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 27.6 ± 3.0 µM

Detail Source Activity Anticancer

Activity Measurement 27.6

Target

Cancer Type Breast Cancer

Cell Line MCF-7

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2017

Evidence 3 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 25.3 ± 2.5 µM

Detail Source Activity Anticancer

Activity Measurement 25.3

Target

Cancer Type Breast Cancer

Cell Line MCF-7/ADM

Tissue Affected Breast

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2017

Evidence 4 Activity

Activity

Activity Endpoint IC50

Activity Raw

IC50 = 32.6 ± 3.4 µM

Detail Source Activity Anticancer

Activity Measurement 32.6

Target

Cancer Type Leukemia Cancer

Cell Line K-562/ADM

Tissue Affected Blood

Assay & Model

Assay MTT assay

Testing Time 48-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2017

Evidence 5 Activity

Activity

Activity Raw

~40-60% LDH release at 8 µM

Detail Source Activity Anticancer

Target

Cancer Type Leukemia Cancer

Cell Line K-562

Tissue Affected Blood

Assay & Model

Assay LDH leakage assay

Testing Time 24-h

Source & Reference

Database Source CancerPPD 2.0 dbACP

Source CancerPPD2

Year 2017